Equity Profile

VCYT

Veracyte, Inc.

Health CareBiotechnology$4.6B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Veracyte, Inc. is a biotechnology company focused on improving patient outcomes through innovative genomic diagnostics....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and generate sales, crucial for sustaining operations and innovation.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

VCYT Q2-2026 Earnings Preview

Context

Company Snapshot

Veracyte, Inc. is a biotechnology company focused on improving patient outcomes through innovative genomic diagnostics. Operating in the health care sector, Veracyte's products help physicians make more informed decisions, particularly in cancer diagnosis and treatment, which is increasingly important as personalized medicine gains traction.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+367.92%

Avg Stock Reaction

+0.09%

Last Quarter Recap

In Q1-2026, Veracyte reported an impressive EPS of $0.52, significantly exceeding expectations. However, revenue figures were not disclosed, leaving some uncertainty about overall performance.

Management Promises & Guidance

Continued focus on expanding product offerings in genomic diagnostics.
Commitment to enhancing patient outcomes through innovative solutions.
Plans to increase market penetration in existing and new regions.

Expectations

Wall Street Expectations

Overall, expectations are mixed as Veracyte has consistently beaten EPS estimates in recent quarters, but the lack of revenue guidance creates uncertainty.

Bull Case

If Veracyte maintains its trend of beating EPS estimates and shows strong revenue growth, it could signal robust demand for its products, leading to a positive market reaction.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a decline in stock price, especially given the high implied volatility in options.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the reported EPS be this quarter?

Given Veracyte's strong history of EPS surprises, the market will closely watch this figure to gauge ongoing profitability.

What are the adoption rates for new products launched?

High adoption rates could indicate strong future revenue growth, while low rates may raise concerns about market acceptance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Veracyte's ability to continue its EPS growth trajectory despite the lack of revenue guidance, as historical performance shows strong resilience.

Supporting Evidence

Veracyte has consistently beaten EPS estimates, indicating strong operational execution.

The options market is pricing in a significant move, suggesting traders expect volatility that could favor the stock's upward potential.

Key Risk

If the reported EPS exceeds $0.55, it could challenge the cautious sentiment currently reflected in the stock price.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Veracyte can maintain its impressive EPS growth amidst uncertain revenue disclosures.

Bull Confirmed If

An EPS of $0.55 or higher would confirm the bull case, indicating continued strong performance.

Bear Confirmed If

An EPS below $0.40 would confirm the bear case, suggesting potential issues with profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±17.32%

Historical Avg

±1.7%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect notable volatility around the earnings announcement.

Options are pricing ±17.3% while VCYT has averaged ±1.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

80.2%

Calls (4K)P/C Ratio: 0.00Puts (600)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Veracyte beats expectations, history suggests the stock could rise by around 0.09% on the first day, confirming strong demand for its products.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance from management.

Miss

A miss could lead to a decline, with historical patterns suggesting a potential drop of around 1.71% on the first day.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

2 buys·0 sells

Members

House only

Est. Notional

$2,002.00–$30,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
2

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product adoption rates for new diagnostics.
2Management's outlook on revenue growth for the upcoming quarters.
3Details on market expansion strategies and geographic penetration.
4Insights into competitive positioning within the biotechnology sector.
5Any commentary on regulatory developments affecting product launches.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Veracyte, Inc. is a biotechnology company focused on improving patient outcomes through innovative genomic diagnostics....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and generate sales, crucial for sustaining operations and innovation.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

VCYT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+367.92%

Avg Stock Reaction

+0.09%

Last Quarter Recap

In Q1-2026, Veracyte reported an impressive EPS of $0.52, significantly exceeding expectations. However, revenue figures were not disclosed, leaving some uncertainty about overall performance.

Management Promises & Guidance

Continued focus on expanding product offerings in genomic diagnostics.
Commitment to enhancing patient outcomes through innovative solutions.
Plans to increase market penetration in existing and new regions.

Expectations

Wall Street Expectations

Overall, expectations are mixed as Veracyte has consistently beaten EPS estimates in recent quarters, but the lack of revenue guidance creates uncertainty.

Bull Case

If Veracyte maintains its trend of beating EPS estimates and shows strong revenue growth, it could signal robust demand for its products, leading to a positive market reaction.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a decline in stock price, especially given the high implied volatility in options.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the reported EPS be this quarter?

Given Veracyte's strong history of EPS surprises, the market will closely watch this figure to gauge ongoing profitability.

What are the adoption rates for new products launched?

High adoption rates could indicate strong future revenue growth, while low rates may raise concerns about market acceptance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Veracyte's ability to continue its EPS growth trajectory despite the lack of revenue guidance, as historical performance shows strong resilience.

Supporting Evidence

Veracyte has consistently beaten EPS estimates, indicating strong operational execution.

The options market is pricing in a significant move, suggesting traders expect volatility that could favor the stock's upward potential.

Key Risk

If the reported EPS exceeds $0.55, it could challenge the cautious sentiment currently reflected in the stock price.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Veracyte can maintain its impressive EPS growth amidst uncertain revenue disclosures.

Bull Confirmed If

An EPS of $0.55 or higher would confirm the bull case, indicating continued strong performance.

Bear Confirmed If

An EPS below $0.40 would confirm the bear case, suggesting potential issues with profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±17.32%

Historical Avg

±1.7%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect notable volatility around the earnings announcement.

Options are pricing ±17.3% while VCYT has averaged ±1.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

80.2%

Calls (4K)P/C Ratio: 0.00Puts (600)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Veracyte beats expectations, history suggests the stock could rise by around 0.09% on the first day, confirming strong demand for its products.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance from management.

Miss

A miss could lead to a decline, with historical patterns suggesting a potential drop of around 1.71% on the first day.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

2 buys·0 sells

Members

House only

Est. Notional

$2,002.00–$30,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
2

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product adoption rates for new diagnostics.
2Management's outlook on revenue growth for the upcoming quarters.
3Details on market expansion strategies and geographic penetration.
4Insights into competitive positioning within the biotechnology sector.
5Any commentary on regulatory developments affecting product launches.